ONCORUS INC (ONCR)

US68236R1032 - Common Stock

0.1206  -0.01 (-8.5%)

Fundamental Rating

2

Overall ONCR gets a fundamental rating of 2 out of 10. We evaluated ONCR against 588 industry peers in the Biotechnology industry. The financial health of ONCR is average, but there are quite some concerns on its profitability. ONCR is valued expensive and it does not seem to be growing.



0

1. Profitability

1.1 Basic Checks

ONCR had negative earnings in the past year.
ONCR had a negative operating cash flow in the past year.
ONCR had negative earnings in each of the past 5 years.
ONCR had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The profitability ratios for ONCR are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ONCR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, ONCR has more shares outstanding
The number of shares outstanding for ONCR has been increased compared to 5 years ago.
The debt/assets ratio for ONCR is higher compared to a year ago.

2.2 Solvency

ONCR has an Altman-Z score of -5.89. This is a bad value and indicates that ONCR is not financially healthy and even has some risk of bankruptcy.
ONCR has a worse Altman-Z score (-5.89) than 68.01% of its industry peers.
ONCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.89
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ONCR has a Current Ratio of 1.50. This is a normal value and indicates that ONCR is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.50, ONCR is doing worse than 81.67% of the companies in the same industry.
ONCR has a Quick Ratio of 1.50. This is a normal value and indicates that ONCR is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.50, ONCR is not doing good in the industry: 80.55% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.5
Quick Ratio 1.5

1

3. Growth

3.1 Past

ONCR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.78%.
EPS 1Y (TTM)-28.78%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-71.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, ONCR will show a very strong growth in Earnings Per Share. The EPS will grow by 21.17% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.04%
EPS Next 2Y30.28%
EPS Next 3Y21.17%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ONCR. In the last year negative earnings were reported.
Also next year ONCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ONCR's earnings are expected to grow with 21.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.28%
EPS Next 3Y21.17%

0

5. Dividend

5.1 Amount

ONCR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ONCORUS INC

NASDAQ:ONCR (6/20/2023, 7:14:14 PM)

0.1206

-0.01 (-8.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.15M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.5
Quick Ratio 1.5
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-28.78%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y34.04%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y